Nusinersen Treatment Outcomes in Later Onset SMA

(2:35)

Nusinersen Treatment for SMA

(4:23)

Nusinersen Treatment for Older Patients with SMA

(3:10)

Nusinersen for Treatment of SMA

(4:9)

New Clinical Data on Adult Nusinersen treated Patients with SMA

(2:24)

Real-World Experience Treating SMA With Nusinersen

(2:49)

Nusinersen (SpinrazaTM): The First FDA Approved Treatment for SMA

(32:14)

The Development Journey of Spinraza® (nusinersen): From Advocacy to Treatment and Beyond

(24:1econd)

Cut and Paste: Treating Spinal Muscular Atrophy with Nusinersen

(3:40)

Using Higher Dose of Nusinersen To Treat Spinal Muscular Atrophy

(8:33)

New Clinical Data on Pediatric Nusinersen treated Patients with SMA

(4:21)

Nusinersen Treated Type 1 Patients Older Than 7 Months

(4:18)

Nusinersen: The First Approval for Spinal Muscular Atrophy

(9:2)

Nusinersen: ASO(Anti-Sense- Oligonucleotide) Therapy toward Spinal Muscular Atrophy (SMA) #Code: 198

(7:13)

Nusinersen ENDEAR-SHINE and CHERISH-SHINE for SMA

(3:9)

Spinraza (nusinersen) Approval

(4:35)

Approval of Nusinersen for SMA

(4:27)

The breakthrough treatment giving hope to those with spinal muscular atrophy

(2:59)

Richard Finkel, AAN 2018 – Spinal muscular atrophy (SMA) is a treatable neurodegenerative disease

(5:40)

Nusinersen in Adults With 5q SMA

(6:5)